Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Current Assets (2020 - 2025)

Historic Current Assets for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $224.0 million.

  • Xeris Biopharma Holdings' Current Assets rose 3760.34% to $224.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.0 million, marking a year-over-year increase of 3760.34%. This contributed to the annual value of $167.7 million for FY2024, which is 729.41% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Current Assets is $224.0 million, which was up 3760.34% from $185.6 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Current Assets ranged from a high of $224.0 million in Q3 2025 and a low of $124.4 million during Q3 2021
  • Moreover, its 5-year median value for Current Assets was $163.5 million (2025), whereas its average is $166.1 million.
  • In the last 5 years, Xeris Biopharma Holdings' Current Assets plummeted by 1635.5% in 2023 and then surged by 3760.34% in 2025.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Current Assets stood at $142.6 million in 2021, then skyrocketed by 31.01% to $186.8 million in 2022, then decreased by 16.35% to $156.3 million in 2023, then grew by 7.29% to $167.7 million in 2024, then surged by 33.61% to $224.0 million in 2025.
  • Its last three reported values are $224.0 million in Q3 2025, $185.6 million for Q2 2025, and $163.5 million during Q1 2025.